All ViroStat COVID-19 monoclonal antibodies are validated to react with the nucleocapsid of common variants circulating, including UK B.1.1.7, South Africa B.1.351 and Brazil P.1, ensuring that the variants will be detected with these antibodies.
Variants of SARS-CoV-2 have evolved due to mutations in the spike protein; however, most antigen detection tests target the nucleocapsid of the virus with the use of antibody pairs. While the nucleocapsid is relatively conserved in comparison to the spike protein, mutations also occur in the nucleocapsid. If the antibody pair used for detection now fails to bind to this antigen because of a mutation, then this could result in a false-negative test result.
Go to the ViroStat website for further information or to download the data sheets for these antibodies.
